Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex has reported strong financial results for Q2 2021, achieving revenues of $713.5 million, a 25.8% year-over-year increase. GAAP diluted EPS surged to $1.76 from $0.24 in the prior period, while adjusted diluted EPS rose 73.6% to $3.35. The company's 2021 guidance remains unchanged, with revenue growth projected between 10.50% and 11.75%. Despite a $28-$32 million revenue headwind expected from its recent respiratory divestiture, the company maintains a positive outlook for its Interventional Urology business, anticipating over 30% growth.
Teleflex (NYSE: TFX) announced a conference call scheduled for July 29, 2021, at 8:00 a.m. ET to discuss its second-quarter financial results and provide an operational update. The call will be accessible via a live audio webcast on teleflex.com. An audio replay will be available later that day, with dial-in options provided for listeners. Teleflex is a global leader in medical technologies, focusing on enhancing patient health and healthcare delivery through innovative solutions.
Teleflex has revealed that the UroLift System yields the lowest overall complication rates among BPH treatments, based on the largest U.S. healthcare claims study presented at the European Association of Urology Congress. An analysis of over 33,000 claims showed a complication rate of 16.3% for the UroLift System at 300 days post-treatment, compared to 19.7% for TURP and 21.6% for GreenLight. The research emphasizes the UroLift System's durability with a low retreatment rate of 6.8% at 1,500 days, comparable to TURP. This data sets a new standard for evaluating minimally invasive BPH procedures.
Teleflex announced presentations at the 36th European Association of Urology Congress highlighting new data on the UroLift System for treating benign prostatic hyperplasia (BPH). Scheduled from July 8-12, these presentations will showcase real-world effectiveness and durability results, emphasizing Real-World Data to complement randomized controlled trials. The UroLift is minimally invasive, preserving sexual function, and has treated over 250,000 men globally. The studies aim to improve understanding of patient outcomes and advance treatment protocols.
Teleflex (NYSE:TFX) announced the completion of the divestiture of a significant portion of its respiratory business to Medline for $286 million, reducing to $274 million due to working capital adjustments. The divested product lines, generating $139 million in 2020, are projected to contribute flat net revenue in 2021. This move is estimated to create a $28-$32 million revenue headwind and a $0.10-$0.15 EPS dilution, approximately 1% of adjusted EPS for 2021. Proceeds will be used to pay down debt, enhancing financial flexibility.
Teleflex has released a survey indicating that men with urinary symptoms due to benign prostatic hyperplasia (BPH) often engage in extreme bathroom planning, impacting their daily activities. Conducted with 1,000 U.S. men aged 45+, the study found that 45.49% avoided enjoyable events due to urinary issues. Over 70% reported diminished energy levels from nighttime awakenings. While many men (66.81%) are interested in minimally invasive procedures, nearly 25% find current BPH medications ineffective. The UroLift System offers a promising alternative for symptom relief.
Teleflex's Executive Vice President and CFO, Thomas Powell, will present at the Raymond James 2021 Human Health Innovation Conference on June 21, 2021, at 8:40 a.m. (ET). A live audio webcast and slide presentation will be available on the Teleflex website.
Teleflex offers a range of medical technologies aimed at improving health and quality of life. Their innovative solutions cover areas such as vascular access, interventional cardiology, anesthesia, and more. The company, listed on the NYSE as TFX, is dedicated to addressing unmet clinical needs.
Teleflex has announced a definitive agreement to sell a significant portion of its Respiratory business to Medline Industries for $286 million, minus $12 million in working capital. The divested product lines generated $139 million in revenue in 2020, with flat growth expected in 2021. The transaction, anticipated to close in early Q3 2021, will incur a revenue headwind of $28-32 million and dilute adjusted earnings per share by $0.10-$0.15. Teleflex plans to use the proceeds to reduce debt and focus on core market segments.
Thomas Powell, Executive Vice President and CFO of Teleflex (NYSE: TFX), will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 3:00 p.m. (ET). The event will include a live audio webcast and a slide presentation available on the investor section of the Teleflex website. Teleflex is known for its innovative medical technologies aimed at improving health outcomes across various fields, including vascular access and emergency medicine. The company emphasizes its commitment to addressing unmet clinical needs through its diverse product portfolio.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 15, 2021, to shareholders of record as of May 14, 2021. This decision reflects the company's commitment to returning value to its shareholders while continuing to focus on improving healthcare through innovative medical technologies across various fields including vascular access and anesthesia. Teleflex maintains a diverse portfolio aimed at meeting unmet clinical needs.